What question did this study set out to answer?

March 5, 20260 citations

Defining Favorable Prognosis in Bone Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.

DKDai KoguchiKitasato University HTHideyasu Tsumura KTKen-ichi TabataKitasato Institute Hospital

Key Points

This research aims to define favorable prognostic factors in bone metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors.
Developed a risk model based on patient characteristics.
Assessed outcomes of patients with varying levels of bone metastases and risk factors.
Compared findings with the existing CHAARTED criteria.
Patients without ≥ 11 bone metastases and high-grade disease may benefit from treatment.
Identified a larger favorable-risk subgroup compared to CHAARTED criteria.
Suggests enhanced precision in treatment selection for prostate cancer patients.

Abstract

This risk model suggests that patients without ≥ 11 BM, ≥ GS9, and ≥ cT3b may benefit from ARSI plus androgen deprivation therapy for mHSPC. Moreover, it identifies a significantly larger favorable-risk subgroup than the CHAARTED criteria, potentially enhancing clinical precision in treatment selection.

AIに質問

Bookmark

View Full Paper

Cite This Study

Koguchi et al. (Tue,) studied this question.

synapsesocial.com/papers/69a91df9d6127c7a504c162d https://doi.org/https://doi.org/10.1002/pros.70152

AIに質問

Bookmark

View Full Paper